Navigation Links
Biovista Inc. Announces Positive Efficacy Results in a Pre-clinical Trial of its BVA-201 Repositioned Drug for Multiple Sclerosis
Date:9/9/2009

CHARLOTTESVILLE, Virginia, September 9 /PRNewswire/ -- Biovista Inc. today announced that BVA-201, its drug targeting Multiple Sclerosis (MS), has shown significant positive results in the MOG-induced Experimental Allergic Encephalomyelitis (EAE) murine model of MS. BVA-201 is an existing drug that Biovista repositioned in MS and is aimed at neuroprotection. It was shown to have both efficacy in reducing symptoms and no toxic effects in this well established model of MS.

"This is our second success in MS in a period of 6 months, with BVA-201 showing efficacy levels closely comparable to those of dexamethasone," said Aris Persidis, Ph.D., President of Biovista. "Histology results are also encouraging, since they seem to confirm our expectations regarding the compound's mechanism of action. What is even more important is that BVA-201 has a known and very favorable safety profile and is already approved for chronic use," Dr. Persidis added.

For a non-confidential information pack on BVA-201 contact Biovista at info@biovista.com.

About Biovista's BVA-201 trial in the MS EAE-MOG model

MS is a chronic inflammatory neurological disease. It is the most frequent non-traumatic disabling neurologic disease among young adults, with over 2.5 million patients worldwide. In the animal proof-of-concept trial, BVA-201 was compared to dexamethasone, a potent anti-inflammatory and immunosuppressive drug that is efficient in accelerating the recovery from MS relapses but too toxic for chronic use. BVA-201 induced a statistically significant reduction of EAE severity, the magnitude of which was directly comparable to that caused by dexamethasone. Furthermore, BVA-201 protected neural axons and myelin against degeneration, as shown in the histology analysis performed. This analysis provided strong evidence that the compound works as a neuroprotective agent as opposed to most currently approved drugs that target the immune system.

About Biovista's repositioning pipeline and technology platform

Biovista applies high-throughput discovery efforts to finding solutions for commercially relevant, unmet medical needs. Biovista's proprietary repositioning technology allows the company's experts to perform mechanism-of-action based analyses and systematically assess clinical outcomes in any therapeutic area of interest, at relatively low cost and very short time spans. The company is presently using this platform to develop its own pipeline of repositioned drugs in areas such as CNS, cardiovascular disease, oncology and auto-immune diseases.

    For more information, please contact:
    Dr Aris Persidis
    Biovista, Inc.
    +1-434-242-6514
    arisp@biovista.com



'/>"/>
SOURCE Biovista Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-601 Repositioned Drug for Epilepsy
2. Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-101 Repositioned Drug for Multiple Sclerosis
3. PharmaNet Development Group Provides Financial Update and Announces Geographic Expansion
4. Encorium Group, Inc. Announces New Business Awards of $8.7 Million, Including Swine Flu (Influenza A H1N1 virus) Vaccine Trial Win;
5. Medivation Announces Participation in Upcoming Conferences
6. VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
7. Clinical Therapeutics Announces the Addition of Michael G. Spigarelli, MD, PhD, as Editor for a Refocused Pediatric, Adolescent, & Maternal Therapeutics Section
8. Verenium Announces Reverse Stock Split to Take Effect September 9
9. BPG Properties, Ltd. Announces 2750 Morris Road in Lansdale, Pennsylvania is for Sale
10. American Oriental Bioengineering Announces September Investor Conferences Participation
11. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Jan. 18, 2017  Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ... immune therapies for operable and inoperable solid tumor cancers, ... Technical Officer of NW Bio, will present at the ... at the Hyatt Regency Hotel in Miami, ... the session entitled "New Therapeutic Approaches – Expanding the ...
(Date:1/18/2017)... , Jan. 18, 2017   Boston Biomedical , ... designed to target cancer stemness pathways, will feature data ... napabucasin, at the 2017 ASCO Gastrointestinal Cancers Symposium, held ... . Napabucasin is an orally-administered investigational ... STAT3. i Cancer stem cells (CSCs) possess the ...
(Date:1/18/2017)... Whitehouse, NJ (PRWEB) , ... January 18, 2017 ... ... access to more and more E&L expertise. Within Albany Molecular Research, Inc. (AMRI), ... doubled in the past year and is planned for further growth in 2017. ...
(Date:1/18/2017)... ... January 18, 2017 , ... BidMed, LLC, ... research and genetic testing lab equipment from two different leading institutes. This highly specialized ... regions of the United States. This 1-day online auction will take place on ...
Breaking Biology Technology:
(Date:1/19/2017)... CLARA, Calif. , Jan. 19, 2017 /PRNewswire/ ... company enhancing user experience and security for consumer ... of next-generation payment processing systems and cybersecurity solutions, ... more banks, enterprises and financial institutions worldwide to ... part of the end-to-end secure user authentication platforms ...
(Date:1/13/2017)... WASHINGTON, N.Y. , Jan. 13, 2017 /PRNewswire/ ... of technology solutions for the homecare industry, including ... of homecare industry expert, Justin Jugs, as Senior ... brings more than 15 years of homecare experience ... team in developing strategic plans to align Sandata,s ...
(Date:1/12/2017)... , January 12, 2017 A new report by Allied Market ... the global biometric technology market is expected to generate revenue of $10.72 billion by ... Continue Reading ... Allied Market Research Logo ...      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) ...
Breaking Biology News(10 mins):